Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...
As connected products blur the line between digital vulnerabilities and physical safety, manufacturers must make a ...
Initial clinical data from the ongoing Phase 1 study of ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, ...
Hubbard County looks ahead toward constructing a trailhead building, cross-country ski and mountain bike trails and campsites ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
When we talk about disasters, we often default to the language of nature. We describe storms as "unprecedented," floods as ...
GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating Phase 2b designPhase 3 initiation targeted for ...
Adopt AI, accelerate development and increase velocity. With 84% of respondents to the Stack Overflow 2025 Developer Survey ...
Discover the evolution of pedestrian-first projects in London, New York, Houston, and Stockholm, reshaping urban landscapes ...
The developers behind Arverne East, NYC's first net-zero community in Far Rockaway, secured $278.8 million for its first ...
EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size ...
The City Council authorized city staff to apply for two grants with a focus on improving downtown infrastructure at last Wednesday’s meeting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback